One year in review
Systemic lupus erythematosus: one year in review 2025
A. Elia1, D. Zucchi2, E. Silvagni3, M. Oliva4, G. Cascarano5, C. Cardelli6, B. Ciribè7, A. Bortoluzzi8, C. Tani9
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiaratani78@gmail.com
CER18646
2025 Vol.43, N°3
PI 0397, PF 0406
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 40072872 [PubMed]
Received: 19/02/2025
Accepted : 03/03/2025
In Press: 12/03/2025
Published: 12/03/2025
Abstract
This review highlights key advancements in systemic lupus erythematosus (SLE) research during 2024, covering pathogenesis, novel therapies, biomarkers, and clinical outcomes. Notable findings include new insights into immune dysregulation, promising therapeutic targets, and real-world data confirming the efficacy of anifrolumab and belimumab. Advances in biomarkers enhance disease monitoring, while multidisciplinary approaches improve reproductive outcomes and quality of life. These developments contribute to refining SLE treatment strategies and patient management.
